E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2018

  • ID: 4576128
  • Report
  • 79 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aileron Therapeutics Inc
  • Amgen Inc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • MORE
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2018

Summary:

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 24 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Leukemias, Osteosarcoma, Refractory Multiple Myeloma, Soft Tissue Sarcoma, Adenoid Cystic Carcinoma (ACC), Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Dedifferentiated Liposarcoma, Essential Thrombocythemia, Follicular Lymphoma, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Vitreoretinopathy (PVR), Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma and Well Differentiated Liposarcoma.

The latest report E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2018, outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
  • The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aileron Therapeutics Inc
  • Amgen Inc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

Amgen Inc

Ascentage Pharma Group Corp Ltd

Boehringer Ingelheim GmbH

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Novartis AG

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles

ALRN-6924 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-7209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-0252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGM-097 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTX-50 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-3032 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-5272 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HDM-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idasanutlin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISA-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMRi-64 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-8994 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit E3 Ubiquitin-Protein Ligase Mdm2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit MDM2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit MDM2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mdm2 and MdmX for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit MDMX and MDM2 for Solid and Liquid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones

Featured News & Press Releases

May 22, 2018: Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute

May 15, 2018: Aileron Therapeutics Announces Changes to Management

Apr 11, 2018: Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia

Mar 28, 2018: Aileron Therapeutics Announces Expansion of Scientific Advisory Board

Mar 19, 2018: Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors

Dec 11, 2017: Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-5272 at ASH

Nov 01, 2017: Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting

Aug 24, 2017: Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting

Jun 03, 2017: Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924

May 18, 2017: Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53

Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology

Nov 30, 2016: Daiichi Sankyo Highlights Clinical Data on DS-3032 at the 58th Annual Meeting of the American Society of Hematology

Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53

Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aileron Therapeutics Inc, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

Pipeline by Boehringer Ingelheim GmbH, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by Novartis AG, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aileron Therapeutics Inc
  • Amgen Inc
  • Ascentage Pharma Group Corp Ltd
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll